Edition:
India

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

6.10EUR
20 Nov 2019
Change (% chg)

€0.02 (+0.33%)
Prev Close
€6.08
Open
€6.06
Day's High
€6.14
Day's Low
€6.03
Volume
196,651
Avg. Vol
172,888
52-wk High
€12.52
52-wk Low
€5.40

Latest Key Developments (Source: Significant Developments)

Biocartis Updates On EUR 150 Mln Senior Unsecured Convertible Bonds
Thursday, 14 Nov 2019 

Nov 14 (Reuters) - BIOCARTIS GROUP NV ::REG-PRESS RELEASE BIOCARTIS GROUP NV: LISTING OF THE EUR 150 MILLION SENIOR UNSECURED CONVERTIBLE BONDS DUE 9 MAY 2024.EUR 150 MILLION 4.00% CONVERTIBLE BONDS DUE 2024 HAVE BEEN ADMITTED TO TRADING AND LISTING ON EURONEXT BRUSSELS.  Full Article

Biocartis Group Q3 Cash Position Up At 197 Million Euros
Thursday, 14 Nov 2019 

Nov 14 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS' CASH POSITION END Q3 2019 AMOUNTED TO EUR 197 MILLION.YEAR-OVER-YEAR VOLUME GROWTH OF 27% FOR Q3 2019.FULL YEAR 2019 GUIDANCE REITERATED.TARGETED CASH POSITION IN THE RANGE OF EUR 170 MLN - EUR 175 MLN BY YEAR END.  Full Article

Biocartis Updates on Five Idylla Studies
Tuesday, 5 Nov 2019 

Nov 5 (Reuters) - Biocartis Group NV ::REG-PRESS RELEASE BIOCARTIS NV: FIVE IDYLLA™ STUDIES TO BE PUBLISHED AT ‘ASSOCIATION FOR MOLECULAR PATHOLOGY' ANNUAL MEETING (US).RESPECTIVE IDYLLA STUDIES SHOWED A STRONG PERFORMANCE OF IDYLLA™ ASSAYS (RUO) COMPARED TO OTHER METHODS INCLUDING IHC AND NGS.  Full Article

Biocartis H1 Net Loss Widens To EUR 29.8 Million
Thursday, 5 Sep 2019 

Sept 5 (Reuters) - Biocartis Group NV ::REG-PRESS RELEASE BIOCARTIS NV: BIOCARTIS ANNOUNCES H1 2019 RESULTS.H1 NET LOSS EUR 29.8 MILLION VERSUS LOSS OF EUR 21.8 MILLION YEAR AGO.H1 TOTAL OPERATING INCOME EUR 17.3 MILLION VERSUS EUR 12.7 MILLION YEAR AGO.CARTRIDGE VOLUME: GUIDANCE FOR FULL YEAR COMMERCIAL IDYLLA™ CARTRIDGE VOLUME GROWTH IS DECREASED AND NOW SET IN RANGE OF 30% - 35%.CASH POSITION: GUIDANCE FOR CASH POSITION NOW SET IN RANGE OF EUR 170M-175M BY YEAR-END.INSTALLED BASE: GUIDANCE FOR FULL YEAR INSTALLED BASE GROWTH IS NOW SET IN RANGE OF 325-350 NEW IDYLLA™ INSTRUMENT PLACEMENTS.  Full Article

Biocartis And Kite Sign Agreement For Development Of Assays Supporting Kite's Therapies
Saturday, 1 Jun 2019 

June 1 (Reuters) - Biocartis Group NV ::BIOCARTIS GROUP NV SAYS BIOCARTIS AND KITE SIGN AGREEMENT FOR DEVELOPMENT OF ASSAYS SUPPORTING KITE'S THERAPIES.BIOCARTIS GROUP NV SAYS FINANCIAL DETAILS ON AGREEMENT WITH KITE ARE NOT DISCLOSED..  Full Article

Biocartis Announces Placement Of Senior Unsecured Convertible Bonds
Thursday, 2 May 2019 

May 2 (Reuters) - BIOCARTIS GROUP NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS ANNOUNCES SUCCESSFUL PLACEMENT OF EUR 150 MILLION SENIOR UNSECURED CONVERTIBLE BONDS DUE 9 MAY 2024.BONDS SHALL BEAR A COUPON OF 4.00% PER ANNUM.CONVERSION PRICE WILL BE SET AT A 25.00% PREMIUM ABOVE REFERENCE PRICE.CLOSING AND SETTLEMENT OF THE OFFERING ARE EXPECTED TO OCCUR ON 9 MAY 2019.  Full Article

Biocartis Group Launches Convertible Bonds Offering Of 125 Million Euros
Thursday, 2 May 2019 

May 2 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES CONVERTIBLE BONDS OFFERING OF EUR 125 MILLION.BONDS WILL BE ISSUED AT 100% OF THEIR PRINCIPAL AMOUNT AND ARE EXPECTED TO BEAR A COUPON OF BETWEEN 3.375% AND 4.125% PER ANNUM, PAYABLE SEMI-ANNUALLY IN ARREAR.CLOSING AND SETTLEMENT OF OFFERING ARE EXPECTED TO TAKE PLACE ON OR AROUND 9 MAY 2019.LAUNCH OF AN OFFERING OF SENIOR UNSECURED CONVERTIBLE BONDS DUE 9 MAY 2024.COMPANY WILL AGREE TO A LOCK-UP UNDERTAKING IN RELATION TO ITS SHARES AND EQUITY-LINKED SECURITIES FOR A PERIOD ENDING 90 CALENDAR DAYS AFTER CLOSING DATE.CONVERSION PRICE EXPECTED AT PREMIUM BETWEEN 22.5% AND 27.5% ABOVE VOLUME WEIGHTED AVERAGE PRICE OF CO'S ORDINARY SHARE ON EURONEXT BRUSSELS FROM MARKET OPEN TO CLOSE OF TRADING ON LAUNCH DAY.LAUNCH OF AN OFFERING OF SENIOR UNSECURED CONVERTIBLE BONDS FOR INITIAL AGGREGATE PRINCIPAL AMOUNT OF EUR 125 MILLION WITH INCREASE OPTION OF UP TO EUR 25 MILLION.  Full Article

Biocartis Group Reiterates FY 2019 Guidance
Thursday, 25 Apr 2019 

April 25 (Reuters) - BIOCARTIS GROUP NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS Q1 2019 BUSINESS UPDATE.FULL YEAR 2019 GUIDANCE REITERATED.CASH POSITION: BIOCARTIS' CASH POSITION AT END OF Q1 2019 AMOUNTED TO EUR 100M (UNAUDITED FIGURE)..EQUITY RAISE: SUCCESSFUL EUR 55.5M PRIVATE PLACEMENT OF NEW SHARES ON 23 JANUARY 2019.AN ACCELERATED RAMP-UP OF US CARTRIDGE VOLUMES IS EXPECTED IN Q2 AND Q3 2019."WE STARTED 2019 WITH A GOOD FIRST QUARTER IN WHICH WE MADE PROGRESS ON ALL FRONTS: COMMERCIALIZATION, MENU EXPANSION, MANUFACTURING, FINANCING AND ORGANIZATION," CEO.  Full Article

Biocartis And Bristol-Myers Squibb Sign Agreement For MSI Testing With Immuno-Oncology Therapies
Tuesday, 12 Mar 2019 

March 12 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS GROUP NV: BIOCARTIS AND BRISTOL-MYERS SQUIBB SIGN COLLABORATION AGREEMENT FOR MSI TESTING WITH IMMUNO-ONCOLOGY THERAPIES.  Full Article

Biocartis Group Launches Equity Placement
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES EQUITY PLACEMENT.ANNOUNCES TODAY LAUNCH OF AN EQUITY OFFERING TO RAISE AN AMOUNT OF APPROXIMATELY EUR 45 MILLION BY MEANS OF A PRIVATE PLACEMENT VIA AN ACCELERATED BOOKBUILD OFFERING.ACCELERATED BOOKBUILDING PROCEDURE WILL COMMENCE IMMEDIATELY.TRADING IN STOCK IS EXPECTED TO RESUME FOLLOWING PUBLICATION OF RESULTS OF OFFERING.TRADING IN BIOCARTIS SHARES ON EURONEXT BRUSSELS WILL BE SUSPENDED DURING BOOKBUILDING PERIOD.  Full Article